Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + Vincristine in Advanced TNBC
NCT05747313Phase 2Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in triple-negative breast cancer (TNBC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05747313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05747313.